［1］XU HT，YAO FS.Primary testicular lymphoma：A SEER analysis of 1 169 cases［J］.Oncology Letters，2019，17(3)：3113-3124.
［2］MA RZ,TIAN L,TAO LY，et al.The survival and prognostic factors of primary testicular lymphoma：two-decade single-center experience［J］.Asian Journal of Andrology，2018，20(6)：615-620.
［3］KING RL,GOODLAD JR,CALAMINICI M,et al.Lymphomas arising in immune-privileged sites：insights into biology，diagnosis and pathogenesis［J］.Virchows Arch，2020，476(5)：647-665.
［4］CHESON BD，FISHER RI，BARRINGTON SF，et al.Recommendations for initial evaluation，staging，and response assessment of Hodgkin and non-Hodgkin lymphoma：the Lugano classification［J］.Journal of Clinical Oncology，2014，32(27)：3059-3068.
［5］CHEAH CY，WIRTH A，SEYMOUR JF.Primary testicular lymphoma［J］.Blood，2014，123(4)：486-493.
［6］MANNISTO S，VAHAMURTO P，POLLARI M，et al.Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma［J］.European Journal of Cancer，2019，2019:11527-11536.
［7］AVILES A，NAMBO MJ，CLETO S，et al.Rituximab and dose-dense chemotherapy in primary testicular lymphoma［J］.Clinical Lymphoma Myeloma，2009，9(5)：386-389.
［8］GUNDRUM JD，MATHIASON MA，MOORE DB，et al.Primary testicular diffuse large B-cell lymphoma：a population-based study on the incidence，natural history，and survival comparison with primary nodal counterpart before and after the introduction of rituximab［J］.Journal of Clinical Oncology，2009，27(31)：5227-5232.
［9］KRIDEL R，TELIO D，VILLA D，et al.Diffuse large B-cell lymphoma with testicular involvement：outcome and risk of CNS relapse in the rituximab era［J］.British Journal of Haematology，2017，176(2)：210-221.
［10］DENG L，XUMONETTE ZY，LOGHAVI S，et al.Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era：a report from the International PTL Consortium［J］.Leukemia，2016，30(2)：361-372.
［11］WU XB,HOU SL,LIU H.Systemic immune inflammation index，ratio of lymphocytes to monocytes，lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients［J］.World Journal of Clinical Cases，2021，9(32)：9825-9834.
［12］VITOLO U，CHIAPPELLA A，FERRERI AJ，et al.First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP，CNS prophylaxis，and contralateral testis irradiation：final results of an international phase Ⅱ trial［J］.Journal of Clinical Oncology，2011，29(20)：2766-2772.
［13］OLLILA TA，OLSZEWSKI AJ.Radiation therapy in primary testicular lymphoma：does practice match the standard of care［J］.Leukemia Lymphoma，2019，60(2)：523-526.
［14］TOKIYA R，YODEN E，KONISHI K，et al.Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma：an analysis of outcomes at a single institution［J］.International Journal of Hematology，2017，106(4)：533-540.
［15］黄文波，杨彦峰，魏梁，等.原发性睾丸弥漫大B细胞淋巴瘤的预后影响因素［J］.现代泌尿外科杂志，2022，27(6)：453-456.
HUANG WB，YANG YF，WEI L，et al.Prognostic factors of primary testicular diffuse large B-cell lymphoma［J］.Journal of Modern Urology，2022，27(6)：453-456.
［16］ 杨萍，甄敬飞，庞萌，等.原发生殖系统弥漫大B细胞淋巴瘤患者临床及生存分析［J］.中华医学杂志，2018，98(20)：1593-1596.
YANG P，ZHEN JF，PANG M，et al.Analysis of survial and treatment outcome of patients with primary diffuse large B cell lymphoma in reproductive system［J］.National Medical Journal of China，2018，98(20)：1593-1596.
［17］ 苏洁敏，郑庆中，黄文荣，等.中期18F-FDG PET/CT检查对评估R-CHOP治疗弥漫性大B细胞淋巴瘤疗效和预后的价值［J］.现代肿瘤医学，2021，29(19)：3453-3457.
SU JM，ZHENG QZ，HUANG WR，et al.The value of medium-term 18F-FDG PET/CT examination in evaluating the efficacy and prognosis of R-CHOP in the treatment of diffuse large B cell lymphoma［J］.Modern Oncology，2021，29(19)：3453-3457.